Clinical Trial Update: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy and safety of Sodium Oligomannate (GV-971) for Alzheimer's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Sodium oligomannate (sodium oligomannate)

Snippet

Sponsor: Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Conditions: Alzheimer's Disease | Phase 4 | Status: RECRUITING